Neuroendocrine Cancers: Advanced Targeted Treatment With Lutetium Lu-177 DOTATATE
Precision-Focused Care for Neuroendocrine Tumors
Theranostics Centers of America provides specialized care for patients with neuroendocrine malignancies through the use of Lutetium Lu-177 DOTATATE, an innovative radiopharmaceutical therapy. This highly targeted treatment delivers radiation directly to neuroendocrine tumor cells, enhancing therapeutic outcomes while reducing exposure to surrounding healthy tissue.
Why Choose Lutetium Lu-177 DOTATATE Therapy?
Targeted Action: Binds to somatostatin receptors on neuroendocrine tumor cells for precise therapy.
Personalized Treatment: Care plans tailored to each patient’s unique clinical and molecular profile.
Outpatient Convenience: Most treatments are performed on an outpatient basis.
Proven Results: Demonstrated efficacy in tumor control and symptom relief for advanced neuroendocrine tumors.
How The Therapy Works
Molecular Imaging: PET or SPECT scans confirm the presence of somatostatin receptor-positive tumors.
Therapy Administration: Lutetium Lu-177 DOTATATE is administered intravenously to target tumor cells.
Targeted Radiation: Delivers a controlled dose of radiation to cancer cells, sparing healthy tissue.
Ongoing Monitoring: Regular follow-up with imaging and lab work to assess response and adjust care as needed.
Who Can Benefit?
Patients with advanced or metastatic neuroendocrine tumors that express somatostatin receptors.
Individuals seeking alternatives to chemotherapy or surgery, or those not responding to other treatments.
Theranostics Centers of America: Your Trusted Partner in Precision Oncology
Specialized Expertise: A multidisciplinary team with deep experience in molecular imaging and radiopharmaceutical therapies.
End-to-End Care: Comprehensive support from initial consultation through ongoing follow-up at every stage of treatment.
Convenient Access: Multiple regional locations designed to make care more accessible.
Interested in Learning More?
If you or someone you care about has been diagnosed with a neuroendocrine malignancy, reach out to TCA Health Careto explore whether Lutetium Lu-177 DOTATATE therapy may be an appropriate treatment option.